Celldex Therapeutics Inc (NAS:CLDX)
$ 32.87 -3.16 (-8.77%) Market Cap: 2.18 Bil Enterprise Value: 1.38 Bil PE Ratio: 0 PB Ratio: 2.68 GF Score: 65/100

Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria Transcript

Feb 26, 2023 / 10:00PM GMT

Feb 26, 2023 / 10:00PM GMT
Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria
Feb 26, 2023 / 10:00PM GMT

=====================
Corporate Participants
=====================
* Anthony S. Marucci
Celldex Therapeutics, Inc. - Founder, President, CEO & Director
* Diane C. Young
Celldex Therapeutics, Inc. - Senior VP & Chief Medical Officer
* Sarah Cavanaugh
Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration
* Tibor Keler
Celldex Therapeutics, Inc. - Founder, Chief Scientific Officer & Executive VP

=====================
Conference Call Participants
=====================
* Evan Porter Taddeo
Guggenheim Securities, LLC, Research Division - Research Analyst
* Kristen Brianne Kluska
Cantor Fitzgerald & Co., Research Division - Analyst
* Samuel Evan Slutsky
LifeSci Capital, LLC, Research Division - Senior Research Analyst
* Thomas Jonathan Smith
SVB Securities LLC, Research Division - Senior MD of Immunology and Metabolism &

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot